	US 12,006,372 B2
	Anti-GARP antibody
Kazuki Satoh, Tokyo (JP); Kazuki Hirahara, Tokyo (JP); Ichiro Watanabe, Tokyo (JP); and Masato Amano, Tokyo (JP)
Assigned to DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
Filed by DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
Filed on Jun. 28, 2021, as Appl. No. 17/361,137.
Application 17/361,137 is a division of application No. 15/761,045, granted, now 11,046,780, previously published as PCT/JP2016/078067, filed on Sep. 23, 2016.
Claims priority of application No. 2015-187488 (JP), filed on Sep. 24, 2015.
Prior Publication US 2022/0010026 A1, Jan. 13, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 16/32 (2006.01); C12N 1/20 (2006.01); C12N 5/10 (2006.01); C12N 5/12 (2006.01); C12N 15/02 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/32 (2013.01) [A61K 39/395 (2013.01); C07K 16/28 (2013.01); C12N 1/20 (2013.01); C12N 5/10 (2013.01); C12N 5/12 (2013.01); C12N 15/02 (2013.01); A61K 2039/505 (2013.01); A61P 35/00 (2018.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)]

24 Claims

1. An antibody that specifically binds Glycoprotein-A Repetitions Predominant (GARP) comprising,

a) CDRH1 consisting of the amino acid sequence at amino acid positions 26 to 35 of SEQ ID NO: 2,

b) CDRH2 consisting of the amino acid sequence at amino acid positions 50 to 66 of SEQ ID NO: 2,

c) CDRH3 consisting of the amino acid sequence at amino acid positions 99 to 107 of SEQ ID NO: 2,

d) CDRL1 consisting of the amino acid sequence at amino acid positions 23 to 36 of SEQ ID NO: 3,

e) CDRL2 consisting of the amino acid sequence at amino acid positions 52 to 58 of SEQ ID NO: 3 and

f) CDRL3 consisting of the amino acid sequence at amino acid positions 91 to 101 of SEQ ID NO: 3.